WO2000066112A1 - Cxcr-4 receptor antagonists - thrombopoietin mimetics - Google Patents
Cxcr-4 receptor antagonists - thrombopoietin mimetics Download PDFInfo
- Publication number
- WO2000066112A1 WO2000066112A1 PCT/US2000/011951 US0011951W WO0066112A1 WO 2000066112 A1 WO2000066112 A1 WO 2000066112A1 US 0011951 W US0011951 W US 0011951W WO 0066112 A1 WO0066112 A1 WO 0066112A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tetraazacyclotetradecane
- pentahydrochloride
- imethy
- pyrazol
- compound according
- Prior art date
Links
- 0 CC(C)(C)OC(N1CCNCCC*CC*CCC1)=O Chemical compound CC(C)(C)OC(N1CCNCCC*CC*CCC1)=O 0.000 description 3
- MDAXKAUIABOHTD-UHFFFAOYSA-N C1CNCCNCCCNCCNC1 Chemical compound C1CNCCNCCCNCCNC1 MDAXKAUIABOHTD-UHFFFAOYSA-N 0.000 description 1
- QRSWNROOKCIKBN-SREVYHEPSA-N CCN(C)/C=C\C=C Chemical compound CCN(C)/C=C\C=C QRSWNROOKCIKBN-SREVYHEPSA-N 0.000 description 1
- RMAXVUZBVLXIKJ-UHFFFAOYSA-N CNCCCNCCN(CCCN)Cc1ccc(CNc2ncc[s]2)cc1 Chemical compound CNCCCNCCN(CCCN)Cc1ccc(CNc2ncc[s]2)cc1 RMAXVUZBVLXIKJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to cyclam derivatives, pharmaceutical compositions containing these compounds, the use of these compounds as CXCR-4 receptor antagonists and to use of these compounds as promoters of thrombopoiesis and megakaryocytopoiesis.
- the CXCR-4 receptor originally known as LESTR/fusin, was shown to be the receptor for the ⁇ or CXC chemokine stromal cell-derived factor- 1 (SDF-1) in 1996 and renamed at this time. SDF- 1 appears to be specific for CXCR-4 and mediates its chemotactic effects via this receptor. The CXCR-4 receptor is widely expressed in a variety of cell types and is implicated in a range of inflammatory responses mediated by SDF- 1.
- the widespread distribution of the receptor leads to its involvement in a number of disease areas including bacterial, fungal and protozoan infections, pain, cancer, diabetes, obesity, anorexia, bulimia, asthma, allergies, Parkinson's disease, acute heart failure, hypotension, hypertension, atherosclerosis, disease states involving angiogenesis. urinary retention, osteoporosis, angina pectoris, myocardial infarction, stroke, ulcers, benign prostatic hypertrophy, migraine, vomiting, psychotic and neurological disorders (e.g. anxiety, schizophrenia, manic depression, depression, delirium, dementia, mental retardation) and dyskinesias (Huntington's disease and Gilles de la Tourette's syndrome), injured or severed spinal cord and other injury related disease states.
- angiogenesis urinary retention, osteoporosis, angina pectoris, myocardial infarction, stroke, ulcers, benign prostatic hypertrophy, migraine, vomiting, psychotic and neurological disorders (e.g. anxiety, schizophrenia, manic depression, depression,
- CXCR-4 has been identified as the co-receptor used by T-tropic HIV- 1 viral strains to infect cells, and antagonists of the receptor may therefore be useful in the treatment of late stage HIV infection and AIDS.
- CXCR-4 receptor antagonists offer a unique approach toward decreasing the pathophysiology associated with the aforementioned diseases.
- Megakaryocytes are bone marrow-derived cells, which are responsible for producing circulating blood platelets. Although comprising ⁇ 0.25% of the bone marrow cells in most species, they have >10 times the volume of typical marrow cells. See Kuter et al. Proc. Natl. Acad. Aci. USA 91 : 1 1104-11108 (1994). Megakaryocytes undergo a process known as endomitosis whereby they replicate their nuclei but fail to undergo cell division and thereby give rise to polypoid cells. In response to a decreased platelet count, the endomitotic rate increases, higher pioidy megakaryocytes are formed, and the number of megakaryocytes may increase up to 3-fold. See Harker J. Gin. Invest. 47: 458-465 (1968). In contrast, in response to an elevated platelet count, the endomitotic rate decreases, lower pioidy megakaryocytes are formed, and the number of megakaryocytes may decrease by 50%.
- TPO thrombopoietin
- TPO is thought to affect megakaryocytopoiesis in several ways: (1) it produces increases in megakaryocyte size and number; (2) it produces an increase in DNA content, in the form of polyploidy, in megakaryocytes; (3) it increases megakaryocyte endomitosis; (4) it produces increased maturation of megakaryocytes; and (5) it produces an increase in the percentage of precursor cells, in the form of small acetylcholinesterase-positive cells, in the bone marrow.
- TPO platelets
- thrombocytes are necessary for blood clotting and when their numbers are very low a patient is at risk of death from catastrophic hemorrhage
- TPO has potential useful application in both the diagnosis and the treatment of various hematological disorders, for example, diseases primarily due to platelet defects.
- Ongoing clinical trials with TPO have indicated that TPO can be administered safely to patients.
- recent studies have provided a basis for the projection of efficacy of TPO therapy in the treatment of thrombocytopenia, and particularly thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transplantation as treatment for cancer or lymphoma. See e.g., McDonald (1992) Am. J. Ped. Hematologv/Oncologv 14: 8-21 (1992).
- Thrombopoietin is a glycoprotein with two distinct regions separated by a potential Arg-Arg cleavage site.
- the amino-terminal region is highly conserved in man and mouse, and has some homology with erythropoietin and interferon-alpha and interferon-beta.
- the carboxy-terminal region shows wide species divergence.
- TPO-R human TPO receptor
- c-mpl human TPO receptor
- TPO-R as a key regulator of megakaryopoiesis
- the present invention involves novel compounds represented by Formulas (I), and (II) hereinbelow, their use as CXCR-4 receptor antagonists and their use as agonist of the TPO receptor
- the present invention further provides methods for antagonizing CXCR-4 receptors in an animal, including humans, which comp ⁇ ses administe ⁇ ng to a subject in need of treatment an effective amount of a compound of Formula (I), and (II) as indicated hereinbelow
- compositions comp ⁇ sing a pharmaceutical carrier and compounds useful m the methods of the invention
- Formula (I) wherein: the -CH2-Z substituent is meta or para to the tetraazacyclotetradecane substituent; Z represents a nitrogen-linked heteroaryl, a substituted nitrogen-linked heteroaryl, a cyclic amine moiety, a substituted cyclic amine moiety, or NY' Y ⁇ where ⁇ l and Y ⁇ are each independently selected from hydrogen, alkyl, substituted alkyl, C3- Ci2aryl, substituted C3-C[2 ryl, cycloalkyl, and substituted cycloalkyl; and
- X is selected from the group consisting of hydrogen, alkyl, C3-C j 2aryl, substituted C3-Ci 2aryl, amino, alkylamino, mtro, hydroxy, alkoxy, halogen, carboxyl and carboxamido; and pharmaceutically acceptable salts, hydrates, solvates, esters and metal complexes thereof.
- Preferred among the presently invented Formula (I) compounds are those in which the nitrogen-linked heteroaryl is selected form: benzimidazole, substituted benzimidazole, phe ⁇ othiazine, substituted phe ⁇ othiazine.
- Particularly preferred among the presently invented Formula (I) compounds are those in which the nitrogen-linked heteroaryl is a substituted benzimidazole.
- Preferred among the presently invented Formula (I) compounds are those in which cyclic amine mioety is selected form: piperazine, pipendme, azacycloheptane, diazacycloheptane, morpholine, azacyclotridecane, 5,6,14,15-dibenzo-l,4-dioxa-8,12- diazacyclopentadeca-5, 14-dien, 1 ,4,7-trioxa- 10-azacyclododecane, 1 ,4,1, 10,-tetraoxa- 13- azacyclopentadecane, 1,4,8,11 -tetraazacyclotetradecane, and diazacyclooctane.
- Formula (I) compounds are those in which cyclic amine mioety is selected form: 1,4-d ⁇ azacycloheptane, azacyclotridecane, 5,6, 14, 15-d ⁇ benzo- 1 ,4-d ⁇ oxa-8, 12-d ⁇ azacyclopentadeca-5, 14-dien, 1,4,8, 1 1 -tetraazacyclotetradecane, and 1,5-d ⁇ azacyclooctane.
- Preferred among the presently invented Formula (I) compounds are those in which C3-C j2aryl, when representing Y ' and or Y ⁇ , is independently selected form- phenyl. quino ne. thiazole, pyrazole and py ⁇ dine.
- Particularly preferred among the presently invented Formula (I) compounds are those in which C3-C j 2aryl, when representing ⁇ l and or Y ⁇ is independently selected form- phenyl and pyrazole
- Preferred among the presently invented Formula (I) compounds are those in which X is selected from hydrogen, mtro and halogen
- heteroaryl as used herein, unless otherwise defined, is meant a cyclic or polycyclic aromatic ring containing from 3 to 16 carbon atoms and containing one to three heteroatoms, provided that one of the heteroatoms is nitrogen and provided that when the number of carbon atoms is 3 the aromatic ⁇ ng contains at least two heteroatoms
- heteroaryl as used herein include benzimidazole and phenothiazine
- cyclic amine moiety as used herein, unless otherwise defined, is meant a nitrogen-linked, non-aromatic, cyclic or polycyclic ring system containing from about 5 to 24 atoms; of which 1 to 4 are nitrogen atoms and 0 to 4 are oxygen atoms, which heteroatoms being separated by 2 or more carbon atoms, wherein the moiety comp ⁇ ses 0 to 2 fused aromatic rings
- cyclic amine moiety examples include piperazme, pipe ⁇ dme, azacycloheptane, diazacycloheptane, morphohne, azacyclotridecane, 5,6,14,15-d ⁇ benzo- l,4-d ⁇ oxa-8,12-d ⁇ azacyclopentadeca-5,14-d ⁇ en, 1,4,7-t ⁇ oxa- l 0-azacyclododecane, 1,4,7,10,-tetraoxa- 13-azacyclopentadecane, 1,4,8,1 1 -tetraazacyclotetradecane, and 1,5- diazacyclooctane
- C3-Ci 2aryl as used herein, unless otherwise defined, is meant a cyclic or polycyclic aromatic nng containing from 3 to 12 carbon atoms and optionally containing one to three heteroatoms, provided that when the number of carbon atoms is 3 the aromatic ring contains at least two heteroatoms and provided that when the number of carbon atoms is 4 the aromatic ⁇ ng contains at least one heteroatom
- C3-C j 2aryl examples include phenyl, benzimidazole, phenothiazine, quinohne, thiazole, pyrazole, py ⁇ dine, py ⁇ midine, naphthyl, 3,4- methylenedioxyphenyl and biphenyl
- heteroatom as used herein is meant oxygen, nitrogen or sulfur
- halogen as used herein is meant a substituent selected from bromide, iodide, chlonde and fluo ⁇ de
- cycloalkyl as used herein unless otherwise defined, is meant a nonaromatic, unsaturated or saturated, cyclic or polycyclic C3-C12
- cycloalkyl and substituted cycloalkvl substituents as used herein include cyclohexyl, 4-hydroxy-cyclohexyl, 2-ethylcyclohexyl, propyl 4- methoxycyclohexyl, 4-methoxycyclohexyl, 4-carboxycyclohexyl and cyclopentyl
- substituted as used herein, unless otherwise defined, is meant that the subject chemical moiety has one or more substituents selected from the group consisting of guanidmo, hydroxyalkyl, alkoxy, acyloxy, alkyl, py ⁇ dyl, py ⁇ midyl, ammo, alkylamino, dialkylammo, [( 1,4,8,1 l,-tetraazacyclotetradecan-l-ylmethyl)phenylmethyl], 3,4- methylenedioxyphenylmethyl, phenylalkyl, phenyl
- alkoxy as used herein is meant -Oalkyl where alkyl is as described herein including -OCH3 and -OC(CH3) 2 CH3.
- acyloxy as used herein is meant -OC(0)alkyl where alkyl is as described herein
- Examples of acyloxy substituents as used herein include. -OC(0)CH3, - OC(0)CH(CH 3 ) 2 and -OC(0)(CH 2 )3CH 3 .
- N-acylamino as used herein is meant -N(H)C(0)alkyl, where alkyl is as desc ⁇ bed herein.
- Examples of N-acylammo substituents as used herein include- - N(H)C(0)CH 3 , -N(H)C(0)CH(CH 3 ) 2 and -N(H)C(0)(CH 2 )3CH 3 .
- alkyl and de ⁇ vatives thereof and in all carbon chains as used herein is meant a linear or branched, saturated or unsaturated hydrocarbon chain having C j -C 12 carbon atoms
- treating and de ⁇ vatives thereof as used herein, is meant prophylatic or therapeutic therapy.
- Y' moiety can be optionally substituted by a substituent selected from the group consisting of alkyl, alkoxy, halogen and carboxy;
- A represents an X -substituted aryl or heteroaryl ring wherein X' is selected from the group consisting of hydrogen, alkyl, aryl, amino, alkylammo, nitro, hydroxy, alkoxy, halogen, carboxyl, and carboxamido; provided that the YCH2 groups are arranged meta or para to each other.
- Preferred compounds, having formula (I), useful in the present invention are selected from the group consisting of: l-[4-(4- Acetyl- l-piperazinomethyl)phenylmethyl]- 1 ,4,8, 11 -tetraazacyclotetradecane pentahydrochloride; l-[4-(l ,4-Diazacycloheptan- l-ylmethyl)phenylmethyl]- 1 ,4,8, 11 -tetraazacyclotetradecane hexahydrochloride; l-[4-(Azacycloheptan-l-ylmethyl)phenylmethyl]- l,4,8, l l-tetraazacyclotetradecane pentahydrochloride; l-[4-( 1 -Piperidinomethy phenylmethyl ]- 1 ,4,8, 1 1 -tetraazacyclotetradecane pentahydrochloride; 1 -[4
- the most preferred compounds included in the present invention are selected from the group consisting of: l-[4-( 1 ,5-Diazacyclooctan- 1 -ylmethyOpheny Imethyl]- 1 ,4,8, 1 1 -tetraazacyclotetradecane hexahydrochloride; 1 -[4-(2-Guanidinobenzimidazol- 1 -y lmethyl)phenylmethy 1]- 1 ,4,8, 11 - tetraazacyclotetradecane pentahydrochloride; l-[4-(5,6,14,15-Dibenzo- l,4-dioxa-8,12-diazacyclopentadeca-5, 14-dien-8- ylmethyOpheny Imethyl]- 1,4,8, 11 -tetraazacyclotetradecane hexahydrochloride; l-[4-(Azacyclotridecan- l-yl
- Preferred compounds of formula (II) are selected from the group consisting of: l,4-Bis[2-(2-benz ⁇ m ⁇ dazolylam ⁇ no)-5,5-di(2-py ⁇ dyI)-4-oxo-5H- ⁇ m ⁇ dazol ⁇ n-3- ylmethyl]benzene bis-t ⁇ fluoroacetic acid salt;
- compositions of the present invention are pharmaceutically acceptable salts and complexes.
- Preferred are the zinc, copper, nickel, cobalt and rhodium complexes, hydrochlonde, hydrobromide and t ⁇ fluoroacetate salts
- the compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms All of these compounds and diastereomers are contemplated to be within the scope of the present invention
- the compounds of Formulas (I) and (II) are prepared as shown in Schemes I to IV below wherein the pendent substituents (X, Z, A, Y', Y' , Y ⁇ and XO are as defined in formulas 1 and 2 and provided that the pendent substituents do not include any such substituents that render inoperative the processes of Schemes I the IV. All of the starting materials are commercially available or are readily made from commercially available starting materials by those of skill in the art.
- the present compounds have been found to act as CXCR-4 receptor antagonist they are useful for the treatment of diseases including but not limited to bacterial, fungal and protozoan infections, pain, thrombocytopenia, cancer, diabetes, obesity, anorexia, bulimia, asthma, allergies, Parkinson s disease, acute heart failure, hypotension, hypertension, neural damage, atherosclerosis, urinary retention, osteoporosis, angina pecto ⁇ s, myocardial infarction, stroke, ulcers, benign prostatic hypertrophy, migraine, angiogenesis, vomiting, psychotic and neurological disorders (e g anxiety, schizophrenia, manic depression, depression, deh ⁇ um, dementia, mental retardation) and dyskmesias (Huntington's disease and Gilles de la Tourette's syndrome), viral infections, such as HIV infection in patients having clinical signs of AIDS and for the treatment of asymptomatic HIV- ⁇ nfected subjects
- the present compounds are also useful for the treatment of an injured or severed spinal cord and other injury-related disease states
- the treatment of thrombocytopenia is accomplished by enhancing the production of platelets
- thrombocytopenia is accomplished by enhancing the production of platelets
- 'co-administe ⁇ ng ' and derivatives thereof as used herein when directed to the TPO mimetic aspect of this invention is meant either simultaneous administration or any manner of separate sequential administration of a TPO mimetic compound, as described herein, and a further active ingredient or ingredients, known to treat thrombocytopenia, including chemotherapy-induced thrombocytopenia and bone marrow transplantation and other conditions with depressed platelet production
- the compounds are administered in a close time proximity to each other
- the compounds are administered in the same dosage form, e g one compound may be administered topicallv and another compound may be administered orally Because the compounds of the present invention have been found to be active as
- TPO mimetics they exhibit therapeutic utility in treating thrombocytopenia and other conditions with depressed platelet production
- TPO receptor in a Luciferase assay such as described in Lamb, et al , Nucleic Acids Research 23 3283-3289 (1995) and Seidel. et al . Proc Natl Acad Sci . USA 92 3041- 3045 (1995) by substituting a TPO-responsive BaF3 cell line (Vigon et al Proc Natl Acad Sci USA 1992, 89, 5640-5644) for the HepG2 cells utilized therein
- the mu ⁇ ne BaF3 cells express TPO receptors and closely match the pattern of STAT (signal transducers and activators of transcription) activation observed in primary mu ⁇ ne and human bone marrow cells in response to TPO
- UT-7/TPO leukemic megakaryoblastic cell line ( Komatsu, N et al , Blood, 1996, 87, 4552-4560) UT-7/TPO cells express TPO-R and are absolutely dependent on the presence of TPO for growth and survival Likewise, some of the most preferred compounds of this invention were also positive in stimulating the maturation of megakaryocytes from human bone marrow cells In this assay, purified human CD34+ progenitor cells were incubated in liquid culture with test compounds for 10 days and the number of cells expressing the transmembrane glycoprotein CD41 (gpllb), a megakaryocytic marker, was then measured by flow cytometry (see Cwirla, S E et al Science, 1997, 276, 1696-1699)
- the pharmaceutically active compounds within the scope of this invention are useful as TPO mimetics in mammals, including humans, in need thereof
- Some of the preferred compounds within the scope of the invention showed activation from about 5% to 100% of control (control is the maximal response to TPO) at a concentration of 0 1 -30 uM in the luciferase assay
- the preferred compounds of the invention also promoted the proliferation of UT-7/TPO cells at a concentration of 0 1 to 30 uM.
- the preferred compounds of the invention also showed activity in the CD41 megakaryocytic assay at a concentration of 0 1 to 30 uM
- the activity of the compound of Example 46 in the luciferase assay is 86% of maximal TPO effect with an EC50 of 2.1 uM
- One aspect of the present invention therefor provides a method of treating thrombocytopenia and other conditions with depressed platelet production, which comprises administering a compound of Formula (I) or (II), as described above, in a quantity effective to enhance platelet production
- the compounds of Formulas (I) and (II) also provide for a method of treating the above indicated disease states because of their demonstrated ability to act as TPO mimetics
- the drug may be administered to a patient in need thereof by any conventional route of administration, including, but not limited to, intravenous, intramuscular, oral, subcutaneous, intradermal, and parenteral
- the present invention therefor provides a method of treating thrombocytopenia and other conditions with depressed platelet production, which comprises administering a compound of Formula (I) or (II), as desc ⁇ bed above, in a quantity effective to enhance platelet production
- the compounds of Formulas (I) and (II) also provide for a method of treating the above indicated disease states because of their demonstrated ability to act as TPO mimetics
- the drug may be administered to a patient in need thereof by any conventional route of administration, including, but not limited to, intravenous, intramuscular, oral, subcutaneous, intradermal, and parenteral
- the pharmaceutical preparations are made following conventional techniques of a pharmaceutical chemist involving mixing, granulating, and compressing, when necessary, for tablet forms, or mixing, filling and dissolving the ingredients, as appropriate, to give the desired oral or parenteral products
- Doses of the presently invented pharmaceutically active compounds in a pharmaceutical dosage unit as described above will be an efficacious, nontoxic quantity preferably selected from the range of 0 001 - 100 mg/kg of active compound, preferably 0001 - 50 mg/kg
- the selected dose is administered preferably from 1-6 times daily, orally or parenterally
- Preferred forms of parenteral administration include topically, rectally, transdermally, by injection and continuously by infusion Oral dosage units for human administration preferably contain from 0 05 to 3500 mg of active compound Oral administration, which uses lower dosages is preferred
- Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular active in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition Additional factors depending on the particular patient being treated will result in a need to adjust dosages, including patient age, weight, diet, and time of administration
- the method of this invention of inducing TPO mimetic activity in mammals, including humans, comp ⁇ ses administe ⁇ ng to a subject in need of such activity an effective TPO mimetic amount of a pharmaceutically active compound of the present invention also provides for the use of a compound of Formula (I) or (II) in the manufacture of a medicament for use as a TPO mimetic
- the invention also provides for the use of a compound of Formula (I) or (II) in the manufacture of a medicament for use in therapy
- the invention also provides for the use of a compound of Formula (I) or (II) in the manufacture of a medicament for use in enhancing platelet production
- the invention also provides for the use of a compound of Formula (I) or (II) in the manufacture of a medicament for use in treating thrombocytopenia
- the invention also provides for a pharmaceutical composition for use as a TPO mimetic which comp ⁇ ses a compound of Formula (I) or (II) and a pharmaceutically acceptable earner
- a pharmaceutical composition for use in the treatment of thrombocytopenia which comp ⁇ ses a compound of Formula (I) or (II) and a pharmaceutically acceptable carrier
- the invention also provides for a pharmaceutical composition for use in enhancing platelet production which comprises a compound of Formula (I) or (II) and a pharmaceutically acceptable earner
- the pharmaceutically active compounds of the present invention can be co-administered with further active ingredients, such as other compounds known to antagonize the CXCR-4 receptor or which exhibit a therapeutic effect on a disease state that is treatable with a CXCR-4 receptor antagonist; or such as other compounds known to treat thrombocytopenia, including chemotherapy-induced thrombocytopenia and bone marrow transplantation and other conditions with depressed platelet production, or compounds known to have utility when used in combination with a TPO mimetic
- Assay plates were seeded with RBL transfected with the SDF- 1 receptor Dye loading buffer (EMEM w/Earl's salts w/ L-glutamine with IX Sulphinpyrozone and 10% BSA, 100 uL) was added to each well, and the plate incubated for 90 minutes at 37 "C The dye loading buffer was aspirated from the plates Hydrolysis buffer (EMEM w/Earl's salts w/ L-glutamine with IX Sulphinpyrozone, lOOuL) was added to each well, and the plate incubated for 10 minutes at 37 °C The cells were washed 3 times with wash buffer (IX Krebs Ringer, 15 mM HEPES, ImM MgCl, 1 mM CaCl with IX Sulphinpyrozone and
- Example l(a)-(c) Following the procedure of Example l(a)-(c), except substituting homopiperazine for 1 -acetylpiperazine, the title compound was prepared (27% overall) H NMR (300MHz, d3-MeOD/D,0) ⁇ 7 67 (d, 2H), 7.50 (d, 2H), 4 52 (s, 2H), 3 98 (s, 2H), 3.90 (s, 2H), 3.62 (m, 2H), 3.53-3 20 (m, 8H), 3.15 (m, 2H), 2.95 (m, 4H), 2.35 (m, 2H), 2.19 ( , 4H), 2.09 ( , 2H), 1.26 (m, 4H).
- Potassium carbonate (3.5 g, 25.3 mmol) was added, followed by the dropwise addition of a solution of l,4,8-t ⁇ -(r-butyloxycarbonyl)- 1 ,4,8, 1 1- tetraazacyclotetradecane (B Boitrel et. al., Tetrahedron Lett , 1995, 36, 4995) (6.0 g, 1 1 98 mmol) in acetonit ⁇ le (100 mL).
- Example 18 l-(4-f(2-aminoethyl)(3-aminopropyl)aminomethyl1phenylmethyl ⁇ - l .4.8.1 1- tetraazacyclotetradecane heptahydrochloride a) (2-phthalimidoethyl)(3-phthalimidoprop- l-yl)amine
- 1,4,8,1 1-tetraazacyclotetradecane pentahydrochloride 200 mg, 0.234 mmol
- ethanol 5 L
- hydrazine hydrate 2.0 mL, 64.2 mmol
- the solvent was evaporated and the residue was slurried in diethyl ether with potassium carbonate.
- the mixture was filtered and the filtrate treated with a 4M solution of
- Example 19 l- ⁇ 4-fdi-(2-pyridyl)aminomethyl]phenylmethvU- 1.4,8.1 1-tetraazacyclotetradecane pentahydrochloride a) l- ⁇ 4-[di-(2-pyridyl)aminomethyljphenylmethyl ⁇ -4,8,l l-tri-(t-butoxycarbonyl)- 1,4,8,11- tetraazacyclotetradecane 2,2 -Dipyridylamine (77 mg, 0.500 mmol) was added to a suspension of sodium hydride (18.8 mg of a 60% dispersion in mineral oil, 0.470 mmol) in anhydrous DMF (10 mL) and the mixture stirred at 25 C for 1 hour under nitrogen.
- sodium hydride 18.8 mg of a 60% dispersion in mineral oil, 0.470 mmol
- Example 20 1 -r4-(2-th ⁇ azolylam ⁇ nomethyl)phenylmethv ⁇ - 1.4.8.1 1 -tetraazacyclotetradecane pentahvdrochlo ⁇ de
- Example 21 1.4-b ⁇ sf2-(2-benz ⁇ m ⁇ dazolylam ⁇ no)-5.5-di(2-py ⁇ dyl)-4-oxo-5H- ⁇ m ⁇ dazol ⁇ n-3- ylmethyllbenzene bis-t ⁇ fluoroacetic acid salt a) 2-(2-benz ⁇ m ⁇ dazolylam ⁇ no)-5,5-d ⁇ (2-pyndyl)-5H- ⁇ m ⁇ dazol ⁇ n-4-one
- Example 22 2.6-b ⁇ sf2-(2-benz ⁇ m ⁇ dazolylam ⁇ no)-5,5-d ⁇ (2-py ⁇ dvO-4-oxo-5H- ⁇ m ⁇ dazol ⁇ n- - ylmethyllpy ⁇ dine bis-t ⁇ fluoroacetic acid salt Following the procedure of Example 21 (a)- 1(b), except substituting 2,6- bis(bromomethyl)pyridine for ⁇ , ⁇ 'dibromo-p-xylene, the title compound was prepared (2% overall). MS (ES+) m/e 842 [M+H] + .
- Potassium carbonate (2.0 g, 14.5 mmol) was added, followed by the dropwise addition of a solution of l,4,8-tri-(f-butyloxycarbonyl)- 1,4,8,11- tetraazacyclotetradecane (B. Boitrel et. al.. Tetrahedron Lett., 1995, 36, 4995) (4.0 g, 7.99 mmol) in acetonitrile (100 mL). The mixture was sti ⁇ ed for 6 hours, cooled and partially evaporated.
- Potassium carbonate (3.5 g, 25.3 mmol) was added, followed by the dropwise addition of a solution of 1 , 4,8-tri-(r-butyloxycarbonyl)- 1,4,8, 11- tetraazacyclotetradecane (B. Boitrel et. al.. Tetrahedron Lett., 1995, 36, 4995) (6.0 g, 1 1.98 mmol) in acetonitrile (100 mL). The mixture was sti ⁇ ed for 6 hours, cooled and partially evaporated.
- Example 26 l,8-bis-[4-( 1.4,8.1 1 -tetraazacyclotetradecan- l-ylmethvOphenylmethyll- 1.4.8.1 1- tetraazacvclotetradecane dodecahydrobromide a) 4, 1 1 -bis(p-toluenesulfony 0- 1 ,8-bis-[4-(4,8, 11 -tris ⁇ p-toluenesulfony 1 ⁇ -1,4,8, 11 - tetraazacyclotetradecan- l-ylmethyl)pheny Imethyl j- 1,4,8, 1 1-tetraazacyclotetradecane A mixture of slightly impure 4,8, l l-t ⁇ s-(p-toluenesulfonyl)- 1,4,8, 1 1- tetraazacyclotetradecane (590 mg, 0,890 mmol) (M.
- Ciampolini et. al., Inorg. Chem., 1987, 26, 3527 a,a -dibromo-p-xylene ( 117 mg, 0.445 mmol), potassium carbonate (369 mg, 2.67 mmol) and acetonitrile (10 mL) was heated at 80 °C for 18h, then cooled and partitioned between water and dichloromethane. Extracts were washed (saturated aqueous NaCl), dried (MgS04) and solvent removed under vacuum.
- Example 28 1 -f4-(N- ⁇ 3-(methylam ⁇ no)propyl l-N-methylam ⁇ nomethyl)phenylmethy 11- 1.4.8.1 1 - tetraazacyclotetradecane hexahydrochloride
- Example 29 l-f4-(N-f 3.4-methylened ⁇ oxyphenylmethvUam ⁇ nomethyl)phenylmethyl1- 1.4.8.1 1 - tetraazacvclotetradecane pentahydrochloride
- a mixture of l-[4-(bromomethyl)phenyimethyl]-4.8, l l-t ⁇ -(f-butoxycarbonyl)- 1,4,8,11-tetraazacyclotetradecane (61 mg, 0.089 mmol) and 3,4- methylenedioxybenzyiamine (40 mg, 0.267 mmol) in ethanol (3 mL) was heated at 80- 90°C for 3 hours The solvent was evaporated and the residue redissolved in DMSO and chromatographed by preparative HPLC (20-80 % acetonit ⁇ le/water + 0 1 % TFA) The resulting purified t ⁇ -(r-butoxycarbonyl) intermediate was dissolved in ethanol (2 5
- Example 35 1 -[5-n ⁇ tro-3-(N- ⁇ 3-(2-th ⁇ enyl)pyrazol-5-yl ⁇ aminomethyOpheny Imethyl]- 1 ,4,8, 11 - tetraazacyclotetradecane pentahydrochlo ⁇ de a) l-[3-(bromomethyl)-5-n ⁇ trophenylmethyl]-4,8, l l-t ⁇ -(r-butoxycarbonyl)- 1,4,8, 11- tetraazacy c lotetradecane
- Example 40 1 -r5-bromo-3-(N- .3-(2-th ⁇ enyl)pyrazol-5-yl J aminomethvOphenylmethyll- 1.4.8.11 - tetraazacyclotetradecane pentahydrochloride a) l-[5-bromo-3-(bromomethyI)phenylmethyl]-4,8, l l-t ⁇ -(r-butoxycarbonyl)- 1,4,8, 1 1- tetraazacyclotetradecane
- Example 47 l-f4-(N-( l-methyl-3-(2-th ⁇ enyl )pyrazol-5-yl )am ⁇ nomethvPphenylmethyl1- 1.4.8.1 1- tetraazacvclotetradecane pentahvdrochlo ⁇ de a) 1 -[4-(bromomethy Opheny Imethy 1]-4,8,1 l-t ⁇ -(r-butoxycarbonyl)-l, 4,8,11- tetraazacy c lotetradecane a,a -Dibromo-p-xylene (36.0 g, 136 mmol) was stirred at 60°C in acetonitrile (500 mL) until it dissolved.
- Example 51 l-r3-(N- ⁇ 3-(4-methylphenvPpyrazol-5-vUaminomethyl)phenylmethyll- 1.4.8.1 1- tetraazacvclotetradecane pentahydrochloride a) l-[3-(bromomethyl)phenylmethylj-4,8,l l-tri-(f-butoxycarbonyl)- 1 ,4,8, 11- tetraazacyclotetradecane a,a -Dibromo-m-xylene (22.0 g, 83.3 mmol) was stirred at 60°C in acetonitrile (350 mL) until it dissolved.
- Potassium carbonate (2.0 g, 14.5 mmol) was added, followed by the dropwise addition of a solution of l,4,8-tri-(r-butyloxycarbonyl)- 1,4,8,1 1- tetraazacyclotetradecane (B. Boitrel et. al., Tetrahedron Lett., 1995, 36, 4995) (4.0 g, 7.99 mmol) in acetonitrile ( 100 mL). The mixture was sti ⁇ ed for 6 hours, cooled and partially evaporated.
- Formulations for pharmaceutical use incorporating compounds of the present invention can be prepared in various forms and with numerous excipients. Examples of such formulations are given below.
- a compound of Formula I or II, (1 mg to 100 mg) is aerosolized from a metered dose inhaler to deliver the desired amount of drug per use.
- Example 57 A compound of Formula I or II, (1 mg to 100 mg) is aerosolized from a metered dose inhaler to deliver the desired amount of drug per use.
- Procedure for tablet formul ation Ingredients 1, 2, 3 and 4 are blended in a suitable mixer/blender. Sufficient water is added portion-wise to the blend with careful mixing after each addition until the mass is of a consistency to permit its conversion to wet granules. The wet mass is converted to granules by passing it through an oscillating granulator using a No. 8 mesh (2.38 mm) screen. The wet granules are then dried in an oven at 140°F (60°C) until dry. The dry granules are lubricated with ingredient No. 5, and the lubricated granules are compressed on a suitable tablet press.
- Example 58 Parenteral Formulation A pharmaceutical composition for parenteral administration is prepared by dissolving an appropriate amount of a compound of Formula I or II in polyethylene glycol with heating. This solution is then diluted with water for injections Ph Eur. (to 100 ml). The solution is then rendered sterile by filtration through a 0.22 micron membrane filter and sealed in sterile containers. Specific Examples of formulations for pharmaceutical use incorporating compounds of the present invention are given below.
- Example 59 - Capsule Composition An oral dosage form for administering a presently invented compound is produced by filing a standard two piece hard gelatin capsule with the ingredients in the proportions shown in Table II, below.
- Example 60 Iniectable Parenteral Composition
- An injectable form for administering a presently invented agonist of the TPO receptor is produced by sti ⁇ ing 1.5% by weight of l-[3-(N- ⁇ 3-(2-guanidinothiazol-4- y Opheny l ⁇ aminomethyl)-5-nitrophenylmethyl]- 1,4,8, 1 1-tetraazacyclotetradecane pentahydrochloride (Compound of Example 39) in 10% by volume propylene glycol in water.
- sucrose, calcium sulfate dihydrate and a presently invented agonist of the TPO receptor are mixed and granulated in the proportions shown with a 10% gelatin solution.
- the wet granules are screened, dried, mixed with the starch, talc and stearic acid, screened and compressed into a tablet.
- Preferred among the compounds of the present invention are compounds of Examples 2 - CXCR4, 7 - CXCR4, 34 - TPO, 39 - TPO, 40 - TPO, 44 - TPO and 51 - TPO.
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00928735A EP1189609A4 (en) | 1999-05-03 | 2000-05-03 | Cxcr-4 receptor antagonists - thrombopoietin mimetics |
AU46924/00A AU4692400A (en) | 1999-05-03 | 2000-05-03 | Cxcr-4 receptor antagonists - thrombopoietin mimetics |
JP2000614997A JP2002543126A (en) | 1999-05-03 | 2000-05-03 | CXCR-4 receptor antagonist-thrombopoietin mimic |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13218999P | 1999-05-03 | 1999-05-03 | |
US13218599P | 1999-05-03 | 1999-05-03 | |
US13219499P | 1999-05-03 | 1999-05-03 | |
US60/132,194 | 1999-05-03 | ||
US60/132,185 | 1999-05-03 | ||
US60/132,189 | 1999-05-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000066112A1 true WO2000066112A1 (en) | 2000-11-09 |
Family
ID=27384258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/011951 WO2000066112A1 (en) | 1999-05-03 | 2000-05-03 | Cxcr-4 receptor antagonists - thrombopoietin mimetics |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1189609A4 (en) |
JP (1) | JP2002543126A (en) |
AU (1) | AU4692400A (en) |
WO (1) | WO2000066112A1 (en) |
Cited By (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001079198A1 (en) * | 2000-04-18 | 2001-10-25 | Agouron Pharmaceuticals, Inc. | Pyrazoles for inhibiting protein kinase |
WO2001085196A2 (en) * | 2000-05-09 | 2001-11-15 | The University Of British Columbia | Cxcr4 antagonist treatment of hematopoietic cells |
JP2003516984A (en) * | 1999-12-17 | 2003-05-20 | アノーメッド・インコーポレイテッド | Heterocyclic compounds that bind chemokine receptors |
WO2003079020A2 (en) * | 2002-03-20 | 2003-09-25 | Dana-Farber Cancer Institute Inc. | Methods and compositions for the identification, assessment, and therapy of small cell lung cancer |
EP1411918A2 (en) * | 2001-07-31 | 2004-04-28 | Anormed Inc. | Methods to mobilize progenitor/stem cells |
WO2005028448A1 (en) * | 2003-09-12 | 2005-03-31 | Merck Patent Gmbh | Benzyl-benzimidazolyl derivatives |
WO2004096154A3 (en) * | 2003-04-29 | 2005-03-31 | Smithkline Beecham Corp | Methods for treating degenerative diseases/injuries |
US6887890B2 (en) | 2000-05-30 | 2005-05-03 | Chugai Seiyaku Kabushiki Kaisha | Compounds exhibiting thrombopoietin-like activities |
WO2005103721A1 (en) * | 2004-04-20 | 2005-11-03 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 4 (cxcr4) |
WO2006129679A1 (en) | 2005-05-31 | 2006-12-07 | Ono Pharmaceutical Co., Ltd. | Spiropiperidine compound and medicinal use thereof |
WO2007049771A1 (en) | 2005-10-28 | 2007-05-03 | Ono Pharmaceutical Co., Ltd. | Compound containing basic group and use thereof |
WO2007058322A1 (en) | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | Basic group-containing compound and use thereof |
WO2007105637A1 (en) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
WO2007132846A1 (en) | 2006-05-16 | 2007-11-22 | Ono Pharmaceutical Co., Ltd. | Compound having acidic group which may be protected, and use thereof |
WO2007142308A1 (en) | 2006-06-07 | 2007-12-13 | Nissan Chemical Industries, Ltd. | Nitrogen-containing heterocyclic compound and thrombopoietin receptor activator |
WO2008016006A1 (en) | 2006-07-31 | 2008-02-07 | Ono Pharmaceutical Co., Ltd. | Compound having cyclic group bound thereto through spiro binding and use thereof |
US7354899B2 (en) | 1998-08-14 | 2008-04-08 | The University Of British Columbia | Methods of treating autoimmune diseases comprising administering CXCR4 antagonists |
US7378098B2 (en) | 2000-04-12 | 2008-05-27 | The University Of British Columbia | CXC chemokine receptor 4 agonist peptides |
US7399776B2 (en) | 2003-04-02 | 2008-07-15 | Taigen Biotechnology | Polyamine compounds for treating chemokine receptor mediated diseases |
US7423011B2 (en) | 1998-03-13 | 2008-09-09 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
US7435718B2 (en) | 2000-05-09 | 2008-10-14 | Chemokine Therapeutics Corp. | CXCR4 antagonist treatment of hematopoietic cells |
US7501526B2 (en) | 2005-01-20 | 2009-03-10 | Taigen Biotechnology | Synthesis of polyamine compounds |
US7504422B2 (en) | 2003-04-02 | 2009-03-17 | Taigen Biotechnology Co. Ltd. | Polyamine compounds |
US7851503B2 (en) | 2002-08-14 | 2010-12-14 | Nissan Chemical Industries, Ltd. | Thrombopoetin receptor activator and process for producing the same |
US7960425B2 (en) | 2005-07-20 | 2011-06-14 | Nissan Chemical Industries, Ltd. | Pyrazole compounds and thrombopoietin receptor activators |
US7968542B2 (en) | 2005-07-15 | 2011-06-28 | Nissan Chemical Industries, Ltd. | Thiophene compounds and thrombopoietin receptor activators |
EP2364982A1 (en) | 2003-04-18 | 2011-09-14 | ONO Pharmaceutical Co., Ltd. | Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof |
US8026368B2 (en) | 2005-11-07 | 2011-09-27 | Nissan Chemical Industries, Ltd. | Hydrazide compounds and thrombopoietin receptor activators |
US8053453B2 (en) | 2002-10-09 | 2011-11-08 | Nissan Chemical Industries, Ltd. | Pyrazolone compounds and thrombopoietin receptor activator |
EP2385040A1 (en) | 2003-03-14 | 2011-11-09 | ONO Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |
US8134013B2 (en) | 2004-12-14 | 2012-03-13 | Nissan Chemical Industries, Ltd. | Amide compound and thrombopoietin receptor activator |
WO2012102937A2 (en) | 2011-01-25 | 2012-08-02 | Irm Llc | Compounds that expand hematopoietic stem cells |
EP2546234A1 (en) | 2004-09-13 | 2013-01-16 | Ono Pharmaceutical Co., Ltd. | Nitrogeneous heterocyclic derivative and medicine containing the same as an active ingredient |
WO2013086436A1 (en) | 2011-12-08 | 2013-06-13 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
WO2013110198A1 (en) | 2012-01-27 | 2013-08-01 | Université de Montréal | Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells |
US8552031B2 (en) | 2004-12-08 | 2013-10-08 | Nissan Chemical Industries, Ltd. | 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators |
US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
US8927281B2 (en) | 2008-10-30 | 2015-01-06 | Irm Llc | Method for expanding hematopoietic stem cells |
WO2016089872A1 (en) * | 2014-12-03 | 2016-06-09 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors |
WO2017030728A1 (en) | 2015-08-17 | 2017-02-23 | Southwestern Oklahoma State University | Compositions comprising macrocycle derivatives incorporating bridged macrocycles and methods of producing and using same |
WO2017216373A1 (en) * | 2016-06-16 | 2017-12-21 | Centre National De La Recherche Scientifique | Cxcr4 receptor-binding compounds useful for increasing interferon level |
US10117931B2 (en) | 2009-04-28 | 2018-11-06 | Kameran Lashkari | Methods for treatment of age-related macular degeneration |
US10647718B2 (en) | 2014-04-22 | 2020-05-12 | Universitéde Montréal | Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells |
US10724028B2 (en) | 2014-10-31 | 2020-07-28 | Nissan Chemical Industries, Ltd. | Ligand-binding fiber and cell culture substrate using said fiber |
WO2020227202A1 (en) * | 2019-05-03 | 2020-11-12 | Children's Hospital Medical Center | Compositions and methods for treating cancer |
US10870624B2 (en) | 2013-05-10 | 2020-12-22 | Karus Therapeutics Limited | Histone deacetylase inhibitors |
US11072625B2 (en) | 2016-10-07 | 2021-07-27 | Glycomimetics, Inc. | Highly potent multimeric e-selectin antagonists |
US11197877B2 (en) | 2017-03-15 | 2021-12-14 | Glycomimetics. Inc. | Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists |
US11291678B2 (en) | 2016-03-02 | 2022-04-05 | Glycomimetics, Inc | Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin |
US11433086B2 (en) | 2016-08-08 | 2022-09-06 | Glycomimetics, Inc. | Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4 |
US11548908B2 (en) | 2017-12-29 | 2023-01-10 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
US11707474B2 (en) | 2018-03-05 | 2023-07-25 | Glycomimetics, Inc. | Methods for treating acute myeloid leukemia and related conditions |
US11712446B2 (en) | 2017-11-30 | 2023-08-01 | Glycomimetics, Inc. | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2005051927A1 (en) * | 2003-11-26 | 2007-12-06 | 株式会社クレハ | Method for culturing CD4-positive T cells by stimulation culture of HIV-1-infected peripheral blood mononuclear cells, and HIV-1 growth inhibitor |
AU2004299040A1 (en) * | 2003-12-15 | 2005-06-30 | Pharmacopeia, Inc. | Heterocyclic aspartyl protease inhibitors |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5583131A (en) * | 1991-12-16 | 1996-12-10 | Johnson Matthey Public Limited Company | Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity |
US5817807A (en) * | 1995-06-06 | 1998-10-06 | Anormed Inc. | Antiviral compounds |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5256675A (en) * | 1989-08-07 | 1993-10-26 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same |
FR2654102B1 (en) * | 1989-11-09 | 1992-01-10 | Air Liquide | PROCESS FOR THE SYNTHESIS OF CYCLIC POLYAZOT DERIVATIVES. |
GB9105489D0 (en) * | 1991-03-15 | 1991-05-01 | Johnson Matthey Plc | Improvements in chemical compounds |
US5612478A (en) * | 1995-03-30 | 1997-03-18 | Johnson Matthey Plc | Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane |
JP2001521897A (en) * | 1997-10-31 | 2001-11-13 | スミスクライン・ビーチャム・コーポレイション | New metal complex |
-
2000
- 2000-05-03 EP EP00928735A patent/EP1189609A4/en not_active Withdrawn
- 2000-05-03 AU AU46924/00A patent/AU4692400A/en not_active Abandoned
- 2000-05-03 JP JP2000614997A patent/JP2002543126A/en not_active Withdrawn
- 2000-05-03 WO PCT/US2000/011951 patent/WO2000066112A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5583131A (en) * | 1991-12-16 | 1996-12-10 | Johnson Matthey Public Limited Company | Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity |
US5817807A (en) * | 1995-06-06 | 1998-10-06 | Anormed Inc. | Antiviral compounds |
Non-Patent Citations (9)
Cited By (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7423011B2 (en) | 1998-03-13 | 2008-09-09 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
US7354899B2 (en) | 1998-08-14 | 2008-04-08 | The University Of British Columbia | Methods of treating autoimmune diseases comprising administering CXCR4 antagonists |
JP2003516984A (en) * | 1999-12-17 | 2003-05-20 | アノーメッド・インコーポレイテッド | Heterocyclic compounds that bind chemokine receptors |
US7378098B2 (en) | 2000-04-12 | 2008-05-27 | The University Of British Columbia | CXC chemokine receptor 4 agonist peptides |
US6462069B2 (en) | 2000-04-18 | 2002-10-08 | Agouron Pharmaceuticals, Inc. | Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases |
WO2001079198A1 (en) * | 2000-04-18 | 2001-10-25 | Agouron Pharmaceuticals, Inc. | Pyrazoles for inhibiting protein kinase |
WO2001085196A2 (en) * | 2000-05-09 | 2001-11-15 | The University Of British Columbia | Cxcr4 antagonist treatment of hematopoietic cells |
WO2001085196A3 (en) * | 2000-05-09 | 2002-02-28 | Univ British Columbia | Cxcr4 antagonist treatment of hematopoietic cells |
US7435718B2 (en) | 2000-05-09 | 2008-10-14 | Chemokine Therapeutics Corp. | CXCR4 antagonist treatment of hematopoietic cells |
US6887890B2 (en) | 2000-05-30 | 2005-05-03 | Chugai Seiyaku Kabushiki Kaisha | Compounds exhibiting thrombopoietin-like activities |
EP3632425A1 (en) * | 2001-07-31 | 2020-04-08 | Genzyme Global S.à.r.l. | Methods to mobilize progenitor/stem cells |
EP1411918A4 (en) * | 2001-07-31 | 2007-11-14 | Anormed Inc | Methods to mobilize progenitor/stem cells |
EP2371361A1 (en) * | 2001-07-31 | 2011-10-05 | Genzyme Global S.à.r.l. | Methods to mobilize progenitor/stem cells |
US7935692B2 (en) | 2001-07-31 | 2011-05-03 | Genzyme Corporation | Methods to mobilize progenitor/stem cells |
US7897590B2 (en) | 2001-07-31 | 2011-03-01 | Genzyme Corporation | Methods to mobilize progenitor/stem cells |
EP1411918A2 (en) * | 2001-07-31 | 2004-04-28 | Anormed Inc. | Methods to mobilize progenitor/stem cells |
WO2003079020A2 (en) * | 2002-03-20 | 2003-09-25 | Dana-Farber Cancer Institute Inc. | Methods and compositions for the identification, assessment, and therapy of small cell lung cancer |
WO2003079020A3 (en) * | 2002-03-20 | 2003-12-24 | Dana Farber Cancer Inst Inc | Methods and compositions for the identification, assessment, and therapy of small cell lung cancer |
US7851503B2 (en) | 2002-08-14 | 2010-12-14 | Nissan Chemical Industries, Ltd. | Thrombopoetin receptor activator and process for producing the same |
US8053453B2 (en) | 2002-10-09 | 2011-11-08 | Nissan Chemical Industries, Ltd. | Pyrazolone compounds and thrombopoietin receptor activator |
EP2385040A1 (en) | 2003-03-14 | 2011-11-09 | ONO Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |
US7399776B2 (en) | 2003-04-02 | 2008-07-15 | Taigen Biotechnology | Polyamine compounds for treating chemokine receptor mediated diseases |
US7504422B2 (en) | 2003-04-02 | 2009-03-17 | Taigen Biotechnology Co. Ltd. | Polyamine compounds |
EP2364982A1 (en) | 2003-04-18 | 2011-09-14 | ONO Pharmaceutical Co., Ltd. | Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof |
WO2004096154A3 (en) * | 2003-04-29 | 2005-03-31 | Smithkline Beecham Corp | Methods for treating degenerative diseases/injuries |
WO2005028448A1 (en) * | 2003-09-12 | 2005-03-31 | Merck Patent Gmbh | Benzyl-benzimidazolyl derivatives |
WO2005103721A1 (en) * | 2004-04-20 | 2005-11-03 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 4 (cxcr4) |
EP2546234A1 (en) | 2004-09-13 | 2013-01-16 | Ono Pharmaceutical Co., Ltd. | Nitrogeneous heterocyclic derivative and medicine containing the same as an active ingredient |
US8552031B2 (en) | 2004-12-08 | 2013-10-08 | Nissan Chemical Industries, Ltd. | 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators |
US8134013B2 (en) | 2004-12-14 | 2012-03-13 | Nissan Chemical Industries, Ltd. | Amide compound and thrombopoietin receptor activator |
US7501526B2 (en) | 2005-01-20 | 2009-03-10 | Taigen Biotechnology | Synthesis of polyamine compounds |
WO2006129679A1 (en) | 2005-05-31 | 2006-12-07 | Ono Pharmaceutical Co., Ltd. | Spiropiperidine compound and medicinal use thereof |
US7968542B2 (en) | 2005-07-15 | 2011-06-28 | Nissan Chemical Industries, Ltd. | Thiophene compounds and thrombopoietin receptor activators |
US7960425B2 (en) | 2005-07-20 | 2011-06-14 | Nissan Chemical Industries, Ltd. | Pyrazole compounds and thrombopoietin receptor activators |
WO2007049771A1 (en) | 2005-10-28 | 2007-05-03 | Ono Pharmaceutical Co., Ltd. | Compound containing basic group and use thereof |
EP2657235A1 (en) | 2005-10-28 | 2013-10-30 | Ono Pharmaceutical Co., Ltd. | Compound containing basic group and use thereof |
US8026368B2 (en) | 2005-11-07 | 2011-09-27 | Nissan Chemical Industries, Ltd. | Hydrazide compounds and thrombopoietin receptor activators |
WO2007058322A1 (en) | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | Basic group-containing compound and use thereof |
WO2007105637A1 (en) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
WO2007132846A1 (en) | 2006-05-16 | 2007-11-22 | Ono Pharmaceutical Co., Ltd. | Compound having acidic group which may be protected, and use thereof |
US8093251B2 (en) | 2006-06-07 | 2012-01-10 | Nissan Chemical Industries, Ltd. | Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators |
WO2007142308A1 (en) | 2006-06-07 | 2007-12-13 | Nissan Chemical Industries, Ltd. | Nitrogen-containing heterocyclic compound and thrombopoietin receptor activator |
WO2008016006A1 (en) | 2006-07-31 | 2008-02-07 | Ono Pharmaceutical Co., Ltd. | Compound having cyclic group bound thereto through spiro binding and use thereof |
US9580426B2 (en) | 2008-10-30 | 2017-02-28 | Novartis Ag | Compounds that expand hematopoietic stem cells |
EP3524604A1 (en) | 2008-10-30 | 2019-08-14 | Novartis AG | Expanded hematopoietic stem cells from cord blood and their therapeutic use |
US8927281B2 (en) | 2008-10-30 | 2015-01-06 | Irm Llc | Method for expanding hematopoietic stem cells |
US10117931B2 (en) | 2009-04-28 | 2018-11-06 | Kameran Lashkari | Methods for treatment of age-related macular degeneration |
US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
WO2012102937A2 (en) | 2011-01-25 | 2012-08-02 | Irm Llc | Compounds that expand hematopoietic stem cells |
US9834755B2 (en) | 2011-12-08 | 2017-12-05 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
WO2013086436A1 (en) | 2011-12-08 | 2013-06-13 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
US10336747B2 (en) | 2012-01-27 | 2019-07-02 | Université de Montréal | Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells |
US9409906B2 (en) | 2012-01-27 | 2016-08-09 | Universite De Montreal | Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells |
WO2013110198A1 (en) | 2012-01-27 | 2013-08-01 | Université de Montréal | Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells |
US10870624B2 (en) | 2013-05-10 | 2020-12-22 | Karus Therapeutics Limited | Histone deacetylase inhibitors |
US10647718B2 (en) | 2014-04-22 | 2020-05-12 | Universitéde Montréal | Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells |
US10724028B2 (en) | 2014-10-31 | 2020-07-28 | Nissan Chemical Industries, Ltd. | Ligand-binding fiber and cell culture substrate using said fiber |
US10519181B2 (en) | 2014-12-03 | 2019-12-31 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors |
WO2016089872A1 (en) * | 2014-12-03 | 2016-06-09 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors |
KR102542750B1 (en) | 2014-12-03 | 2023-06-12 | 글리코미메틱스, 인크. | Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors |
AU2015355136B2 (en) * | 2014-12-03 | 2020-06-25 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors |
CN107108679A (en) * | 2014-12-03 | 2017-08-29 | 糖模拟物有限公司 | E selects the Heterobifunctional inhibitor of albumen and CXCR4 chemokine receptors |
CN107108679B (en) * | 2014-12-03 | 2020-10-23 | 糖模拟物有限公司 | Heterobifunctional inhibitors of E-selectin and CXCR4 chemokine receptors |
KR20170085594A (en) * | 2014-12-03 | 2017-07-24 | 글리코미메틱스, 인크. | Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors |
EP3337519A4 (en) * | 2015-08-17 | 2019-01-09 | Southwestern Oklahoma State University | Compositions comprising macrocycle derivatives incorporating bridged macrocycles and methods of producing and using same |
WO2017030728A1 (en) | 2015-08-17 | 2017-02-23 | Southwestern Oklahoma State University | Compositions comprising macrocycle derivatives incorporating bridged macrocycles and methods of producing and using same |
AU2016307752B2 (en) * | 2015-08-17 | 2020-11-12 | Southwestern Oklahoma State University | Compositions comprising macrocycle derivatives incorporating bridged macrocycles and methods of producing and using same |
US10927108B2 (en) | 2015-08-17 | 2021-02-23 | Southwestern Oklahoma State University | Compositions comprising macrocycle derivatives incorporating bridged macrocycles and methods of producing and using same |
US11291678B2 (en) | 2016-03-02 | 2022-04-05 | Glycomimetics, Inc | Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin |
US11433048B2 (en) | 2016-06-16 | 2022-09-06 | Centre National De La Recherche Scientifique | CXCR4 receptor-binding compounds useful for increasing interferon level |
WO2017216373A1 (en) * | 2016-06-16 | 2017-12-21 | Centre National De La Recherche Scientifique | Cxcr4 receptor-binding compounds useful for increasing interferon level |
US11433086B2 (en) | 2016-08-08 | 2022-09-06 | Glycomimetics, Inc. | Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4 |
US11780873B2 (en) | 2016-10-07 | 2023-10-10 | Glycomimetics, Inc. | Highly potent multimeric e-selectin antagonists |
US11072625B2 (en) | 2016-10-07 | 2021-07-27 | Glycomimetics, Inc. | Highly potent multimeric e-selectin antagonists |
US11878026B2 (en) | 2017-03-15 | 2024-01-23 | Glycomimetics, Inc. | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists |
US11197877B2 (en) | 2017-03-15 | 2021-12-14 | Glycomimetics. Inc. | Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists |
US11712446B2 (en) | 2017-11-30 | 2023-08-01 | Glycomimetics, Inc. | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
US11548908B2 (en) | 2017-12-29 | 2023-01-10 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
US11707474B2 (en) | 2018-03-05 | 2023-07-25 | Glycomimetics, Inc. | Methods for treating acute myeloid leukemia and related conditions |
US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
WO2020227202A1 (en) * | 2019-05-03 | 2020-11-12 | Children's Hospital Medical Center | Compositions and methods for treating cancer |
US11564913B2 (en) | 2019-05-03 | 2023-01-31 | Children's Hospital Medical Center | Compositions and methods for treating cancer |
CN114072385A (en) * | 2019-05-03 | 2022-02-18 | 儿童医院医学中心 | Compositions and methods for treating cancer |
Also Published As
Publication number | Publication date |
---|---|
EP1189609A1 (en) | 2002-03-27 |
EP1189609A4 (en) | 2002-10-30 |
AU4692400A (en) | 2000-11-17 |
JP2002543126A (en) | 2002-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1189609A1 (en) | Cxcr-4 receptor antagonists - thrombopoietin mimetics | |
US6552008B1 (en) | Thrombopoietin mimetics | |
EP1864981B1 (en) | Thrombopoietin mimetics | |
US6670387B1 (en) | Thrombopoietin mimetics | |
AU770564B2 (en) | Thrombopoietin mimetics | |
US7414040B2 (en) | Thrombopoietin mimetics | |
EP1228051A1 (en) | Semicarbazone derivatives and their use as thrombopoietin mimetics | |
US6498155B1 (en) | Methods of treating thrombocytopenia | |
JP5821079B2 (en) | Bicyclo-substituted pyrazolone-azo derivative salt, process for its production and use thereof | |
US20060084682A1 (en) | Thrombopoietin mimetics | |
US20040058990A1 (en) | Thrombopoietin mimetics | |
US6720345B1 (en) | Semicarbazone derivatives and their use as thrombopoietin mimetics | |
US6875786B2 (en) | Thrombopoietin mimetics | |
US6642265B1 (en) | Thrombopoietin mimetics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 46924/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09980502 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 614997 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000928735 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000928735 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000928735 Country of ref document: EP |